Jorg Thomas Bittenbring
Overview
Explore the profile of Jorg Thomas Bittenbring including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Biedermann A, Patra-Kneuer M, Mougiakakos D, Buttner-Herold M, Mangelberger-Eberl D, Berges J, et al.
Haematologica
. 2024 Jun;
109(12):3928-3940.
PMID: 38934068
Macrophages are one of the key mediators of the therapeutic effects exerted by monoclonal antibodies, such as the anti-CD19 antibody tafasitamab, approved in combination with lenalidomide for the treatment of...
2.
Rosar F, Ezziddin S, Bittenbring J, Christofyllakis K, Burgard C
Clin Nucl Med
. 2024 Mar;
49(5):464-465.
PMID: 38456450
We report an 18 F-FDG PET/CT scan of a 47-year-old man diagnosed with diffuse mast cell sarcoma with lymph node, bone, liver, spleen, and lung involvement. This interesting image should...
3.
Hoffmann M, Cavalli G, Fadle N, Cantoni E, Regitz E, Fleser O, et al.
J Clin Immunol
. 2024 Jan;
44(2):45.
PMID: 38231276
Background: Adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA) resemble a continuum of a rare, polygenic IL-1β-driven disease of unknown etiology. Objective: In the present study we sought...
4.
Sabet A, Mader N, Bittenbring J, Khreish F, Grunwald F, Biersack H, et al.
Pharmaceuticals (Basel)
. 2021 Oct;
14(10).
PMID: 34681247
Peptide receptor radionuclide therapy (PRRT) of metastatic neuroendocrine tumors (NET) can be successfully repeated but may eventually be dose-limited. Since Lu-DOTATATE dose limitation may come from hematological rather than renal...
5.
Thurner L, Fadle N, Bittenbring J, Regitz E, Schuck R, Cetin O, et al.
Blood
. 2021 Jan;
137(23):3251-3258.
PMID: 33513604
Low-density lipoprotein (LDL) receptor-related protein-associated protein 1 (LRPAP1) had been identified by B-cell receptor (BCR) expression cloning and subsequent protein array screening as a frequent and proliferation-inducing autoantigen of mantle...
6.
Kaddu-Mulindwa D, Rosolowski M, Ziepert M, Regitz E, Assmann G, Bewarder M, et al.
Eur J Haematol
. 2020 Sep;
106(1):100-104.
PMID: 32997825
Purpose: Previous published data showed an impact of single-nucleotide polymorphisms in the VEGF A and VEGFR2 genes on the survival of patients with various malignancies, among others diffuse large B-cell...
7.
Werner C, Hecksteden A, Morsch A, Zundler J, Wegmann M, Kratzsch J, et al.
Eur Heart J
. 2018 Nov;
40(1):34-46.
PMID: 30496493
Aims: It is unknown whether different training modalities exert differential cellular effects. Telomeres and telomere-associated proteins play a major role in cellular aging with implications for global health. This prospective...
8.
Bochen F, Balensiefer B, Korner S, Bittenbring J, Neumann F, Koch A, et al.
Oncoimmunology
. 2018 Sep;
7(9):e1476817.
PMID: 30228945
Vitamin D deficiency is frequently observed in human cancer patients and a prognostic relevance could be shown for some entities. Additionally, it is known that vitamin D can stimulate the...
9.
Kaddu-Mulindwa D, Bittenbring J, Muller C, Altmeyer S
Dtsch Med Wochenschr
. 2018 Aug;
143(17):1225-1226.
PMID: 30134453
No abstract available.
10.
Bittenbring J, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, et al.
J Clin Oncol
. 2014 Aug;
32(29):3242-8.
PMID: 25135997
Purpose: To investigate the impact and mechanisms of vitamin D deficiency (VDD) on the outcome of elderly patients with diffuse large B-cell lymphoma (DLBCL). Patients And Methods: Three hundred fifty-nine...